NEEDHAM, Mass.--(BUSINESS WIRE)-- Candel Therapeutics, a clinical-stage biotechnology company, developing novel immune-based cancer therapeutics, today announced the appointment of Chris Matheny, PharmD, Ph.D., as vice president, development leader. Dr. Matheny will work closely with other members of the leadership team to continue efforts in building a clinical development organization that will deliver differentiated medicines with the potential to save, extend and improve the lives of cancer patients. “It is a distinct pleasure to have a highly strategic and accomplished drug developer like Chris join the Candel team. His passion for advancing therapeutics for oncology patients aligns perfectly with our steadfast goal of delivering effective oncolytic viral immunotherapies designed to improve survival, while also maintaining quality of life,” said Paul Peter Tak, M.D., Ph.D., president and CEO of Candel Therapeutics. “Chris’s ongoing vision for the oncology space is truly inspiring, and through his leadership and collaboration abilities, we are confident that he will ensure our mission and embolden our team to continue discovering and thinking in new, innovative ways.”